Illumina develops DNA sequencing, array-based, informatics and proteomics technologies for research, clinical and applied markets. Company news commonly covers sequencing instruments and consumables, NovaSeq X demand, DRAGEN software releases, TruPath Genome analytical support, and applications in oncology, reproductive health, agriculture, rare disease and drug discovery.
Illumina updates also include collaborations around precision oncology testing, preventive and population genomics, pediatric cancer and rare disease data, and the Alliance for Genomic Discovery. Financial and corporate news covers revenue trends, operating margins, earnings guidance, share repurchase authorizations, acquisitions in multiomics and proteomics, and board or management changes.
Population genomics programs are expanding globally as nations seek to understand their populations' genetic variations. While early studies like UK Biobank were largely Eurocentric, new initiatives are emerging worldwide to address genetic diversity gaps. Countries including Thailand, Saudi Arabia, UAE, Australia, Singapore, Turkey, and Nigeria are launching sequencing programs to gain population-specific insights and develop their genomics infrastructure.
These programs aim to drive precision medicine and economic development by creating biotech clusters, generating jobs, and attracting international talent and investment. Pharmaceutical companies are particularly interested as genomically-informed drugs are reportedly more likely to reach the market and less expensive to develop.
Illumina has unveiled its MiSeq i100 Series of sequencing systems, designed to make next-generation sequencing (NGS) more accessible. The new benchtop instruments, MiSeq i100 and MiSeq i100 Plus Systems, offer unparalleled speed and simplicity for labs.
Key features include:
- Room-temperature reagent storage and shipping
- 85% reduction in packaging waste
- Run times as fast as four hours
- Cost-effective consumables
- 18 proven end-to-end workflows across 10 applications
- Simplified operations for various experience levels
The MiSeq i100 Series builds on the legacy of the original MiSeq System, incorporating technology from the NovaSeq X Series. It offers flexible output capabilities, with the MiSeq i100 Plus System providing 100 million single-end reads per run, and the MiSeq i100 System offering 25 million.
Early access testing has received positive feedback from customers, highlighting the instrument's speed, flexibility, and ease of use. The MiSeq i100 will be available globally in 2025.
Illumina, Inc. (NASDAQ: ILMN) has announced that it will release its third quarter 2024 financial results after the market closes on Monday, November 4, 2024. Following the release, the company will host a conference call at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.
The call will feature Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, who will discuss the financial and operating results with analysts, investors, and other interested parties. Participants can join the teleconference through Illumina's website investor section or by dialing specific numbers for North American and international callers. The company advises connecting at least ten minutes before the scheduled start time to ensure timely access.
A replay of the conference call will be made available on Illumina's website for a minimum of 30 days following the event.
Illumina (NASDAQ: ILMN) announced that Charles "Chuck" Dadswell will step down as General Counsel and Secretary on October 3, after 11 years of service. Dadswell will remain as an advisor to CEO Jacob Thaysen and the Board of Directors through March 31, 2025. Scott Davies has been named acting General Counsel and Secretary while the company conducts a search for Dadswell's permanent successor.
Dadswell joined Illumina in 2013 and recently oversaw the company's successful challenge in the European Court of Justice regarding the European Commission's jurisdiction over Illumina's acquisition of GRAIL. CEO Jacob Thaysen praised Dadswell's contributions to Illumina's industry leadership. Scott Davies, who joined Illumina in 2009, most recently served as Vice President, Legal – Chief Corporate Counsel and Assistant Secretary.
Illumina's Singapore team participated in the annual Relay for Life Charity Run for the Singapore Cancer Society (SCS), raising US $4940 to support cancer programs. In 2023, over 70% of Illumina employees in Singapore participated in giving and volunteering activities, contributing $122,000 to various charities. The team focused on key causes, including SCS and the Children's Cancer Foundation (CCF).
Illumina's support for SCS included donations, volunteer hours, and funding for programs like empowerHER and Return to Role. Employees also participated in the Hair for Hope campaign for CCF, raising over $60,000. In total, Illumina and its employees donated more than $350,000 to various causes in Singapore and contributed over 4400 volunteer hours in 2023.
The Washington, DC Public Health Laboratory's Next-Generation Sequencing Core is developing an RSV surveillance system to identify circulating strains and their impact on vulnerable populations. Led by Dr. Eric Vaughn, the team aims to understand the molecular aspects of RSV and other pathogens affecting DC's residents, commuters, and tourists.
The core is using the Illumina Microbial Amplicon Prep (IMAP) kit to simplify RSV sequencing. Their preliminary findings suggest possible distinctions between demographics affected by RSV-A and RSV-B strains. The project will expand during the upcoming respiratory illness season, analyzing more samples to create a real-time picture of RSV's impact on different population groups in the district.
This surveillance system will help the DC Department of Health in prevention and outreach services, potentially guiding targeted interventions based on the specific RSV strains affecting different demographics.
The University of Notre Dame is collaborating with NASA and Illumina to monitor forest health using cutting-edge technology. The Global Ecosystem Dynamics Investigation (GEDI) sensor, mounted on the International Space Station, uses lidar to create 3D maps of forests. GEDI's data is combined with genetic sequencing from the University of Notre Dame to understand tree health at an unprecedented level. This collaboration, part of NASA's Applied Earth Observations Innovation Partnership, aims to link genetic data with remote sensing to address large-scale environmental challenges. The project utilizes GEDI's lidar, ECOSTRESS's infrared sensors, and DESIS's color patterns to detect early signs of stress and disease in trees. This innovative approach could transform ecological research and forest management.
Karina Katalina Moreno, a quality control stability scientist at Illumina, has found her American dream after a journey from Monterrey, Mexico. With a biotech engineering degree and a master's from the University of Edinburgh, Moreno joined Illumina in 2023. She's making an impact as the treasurer of iLatinx, an employee resource group, and through her work in reagent stability.
Moreno is actively involved in Hispanic Heritage Month celebrations at Illumina, promoting cultural exchange and diversity. She's also passionate about mentoring young women through initiatives like Girls Who Lead days. An avid athlete, Moreno participates in various sports and finds Illumina to be a safe and inclusive space where she can express her cultural identity freely.
Illumina is supporting a project that combines genomics with citizen science to monitor ocean health in the South-West Pacific region. The Citizens of The Sea project, led by Xavier Pochon from the Cawthron Institute, equips seafaring vessels with environmental DNA (eDNA) sample collection kits. These samples are then analyzed by Sequench laboratory in New Zealand, creating powerful datasets to understand and improve ocean health.
This initiative demonstrates Illumina's commitment to environmental stewardship and sustainable future. The project leverages Illumina's expertise in genomic sequencing to contribute to marine conservation efforts, showcasing the company's involvement in innovative environmental monitoring techniques.
Illumina (NASDAQ: ILMN) has won a significant legal victory as the European Court of Justice (ECJ) ruled that the European Commission lacked jurisdiction over Illumina's acquisition of GRAIL. This decision removes the basis for a 432 million euro fine previously imposed on Illumina. The ruling comes after Illumina's spin-off of GRAIL in June 2024, which resulted in GRAIL becoming an independent public company. Illumina now holds a 14.5% minority stake in GRAIL and will continue to support it with sequencing technology and services. Additionally, in the United States, the FTC Commissioners dismissed the case against Illumina and GRAIL on August 15, 2024, following the successful spin-off, concluding the US proceedings.